Elon Musk Is Compared to a Dictator in Luca Guadagnino's New Movie
It was announced last month that Guadagnino will direct a movie about OpenAI for Amazon MGM Studios. The film will revolve around the period at the artificial intelligence company in 2023 that saw CEO Sam Altman fired and rehired in a handful of days.
The cast of the movie includes Andrew Garfield, Monica Barbaro, and Yura Borisov.
According to Puck, Elon Musk's role as an 'early OpenAI investor turned bitter rival' is explored in the film, though it is not yet clear who will play him.
'He's a minor character, especially after he tries to merge OpenAI into Tesla and then pulls his investment when he's rebuffed,' the article notes. 'But Elon, as famous for loving movies as he is for suing people, is probably not gonna like this portrayal — nor, likely, will his Grok chatbot (Unfortunately for Grok, there are no pro-Hitler references in the script). At one point, Murati says of Musk: 'Elon's not so bad, as far as dictators go.''
Puck also reports that Artificial, which was written by Simon Rich, centers more on Ilya Sutskever than it does on Altman.
'The film, which begins rehearsals next week in Italy, with a planned 2026 release, is actually the story of Ilya Sutskever, the idealistic and naive Israeli machine learning engineer (played by Anora breakout Yura Borisov) who co-founded the nonprofit. After several key breakthroughs, as depicted in the script, Sutskever is leveraged, marginalized, and ultimately betrayed by both his power-hungry friend Altman and the larger Silicon Valley community — with potentially disastrous consequences for all of humanity.'
It is worth noting that Puck got this information after reading a 'recent draft' of the Artificial script; meaning there could still be edits that are made, given that the movie is not yet in production.
The post Elon Musk Is Compared to a Dictator in Luca Guadagnino's New Movie appeared first on ComingSoon.net - Movie Trailers, TV & Streaming News, and More.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNET
an hour ago
- CNET
Today's AI Appreciation Day Feels Weird. Celebrate These Other Made-Up Holidays Instead
July 16 is AI Appreciation Day. So break out the champagne for ChatGPT! Bring gifts of Nvidia chips and cake for Gemini and flowers and training data for Claude. Meta AI has had a particularly rough year, so when you're forced to use it on Instagram, make sure it feels your love. Think that sounds ridiculous? Same. But like most things when it comes to AI, today's Appreciation Day is unbelievably stupid, in a way that's totally on brand. If you've never heard of AI Appreciation Day, don't feel bad. It's not an official US holiday, and its origins are somewhat shady. In 2021, a random LLC crowned July 16 as the holiday while it was promoting a movie about AI. In the following years, AI companies jumped on the trend, posting #AIAppreciationDay posts on social media on July 16. The purpose of this so-called holiday and its fanfare is crystal clear: To convince you that AI is life-changing, earth-shattering, innovative technology worth shelling out your hard-earned cash for. So it's no surprise to see the made-up holiday being celebrated again in 2025. OpenAI, Google and Meta have devoted literal billions of dollars over the past few years to develop the most advanced AI models. AI is nearly impossible to escape online -- it's in our smartphones, social media feeds and search engines. But does that mean it's worthy of a national day of appreciation? I'm an AI reporter, and I spend a lot of time thinking about how the tools available to us affect us individually and as a society. It leaves a queasy feeling in my stomach to dedicate a whole day to uplifting generative AI (and ostensibly, the leaders of the companies producing them) when so much of what AI has wrought has been harmful. I know I'm not alone in this. There are a lot of reasons why you may not feel like celebrating AI. Environmentally, it's a disaster. The data centers that house the servers that power chatbots eat up lots of energy and fresh water, and reports show they often harm the towns they're located in. Writers, artists and creators of all kinds have big concerns about how these AI models are trained on existing, human-generated data. Some have filed lawsuits alleging copyright infringement, with early wins going in the tech companies' favor. (Disclosure: Ziff Davis, CNET's parent company, in April filed a lawsuit against OpenAI, alleging it infringed Ziff Davis copyrights in training and operating its AI systems.) AI is also a huge worry in the workplace in many fields -- not because chatbots or image generators are actually suitable replacements for any one job, but because AI-enthusiastic bosses see the tech as their newest cost-saving holy grail. Educators are worried that students' use of AI is hindering their development of critical thinking and writing skills that are necessary, not only for work, but also needed just generally for life. We don't have time to go into the potential ramifications of letting error-prone AI into our government services and national defense. In short, there's good reason why some experts call the whole AI experiment a con. So if you don't feel like wading into the sycophantic waves of wishing your souped-up autocorrect a happy AI Appreciation Day, here are some other holidays you can celebrate on July 16. David Watsky/CNET National Hot Dog Day If I'm going to celebrate a meaningless holiday invented by marketing companies, it's going to be National Hot Dog Day, not AI Appreciation Day. Fire up the grill -- or stovetop, which is truly the best way to cook a hot dog, according to CNET expert David Watsky. There are a ton of food-related holidays on July 16, including appreciation days for spinach, cherries and corn fritters. You can have a whole feast made of July 16 holiday foods, and I'm positive you can put the recipe together without using ChatGPT. AI-generated recipes can be hit or miss, especially when followed blindly. I can't imagine anything more embarrassing than getting food poisoning because you listened to ChatGPT, frankly (pun intended). And if you're not a wizard in the kitchen, it's also National Personal Chef Day. Francesco Riccardo Iacomino via Getty Images National Snake Day This one I'm less excited about, but I would still rather celebrate snakes than the snake oil salesmen who claim AI is the holy grail, a bulletproof solution to any problem. Amazon MGM Studios National Conrad Fisher/The Summer I Turned Pretty Day OK, I admit it: I made this one up. But the beginning of the final season of Jenny Han's The Summer I Turned Pretty TV series adaptation by Prime Video is way, way more exciting than hallucination-prone AI slop. Team Connie Baby forever. NASA Real days deserving of commemoration While I love a made-up holiday that doesn't give me existential dread, it's worth taking a moment to call out two notable historic events that also happened on July 16. First, the Apollo 11 mission launched on July 16, 1969, and four days later, astronaut Neil Armstrong would be the first man to set foot on the moon. This world-changing scientific feat was accomplished in part because of a computer that ran on 70 watts of power -- the same as an incandescent lightbulb. That's about the same as one single ChatGPT query; OpenAI CEO Sam Altman said one ChatGPT query uses about 0.34 watt-hours, the same as a high-efficiency LED lightbulb uses in a couple of minutes. So you can use the energy equivalent of one lightbulb to send men to the moon in 1969, or one lightbulb today for AI that can't even correctly tell us what year it is. Katy Perry's endlessly mockable Blue Origin space flight certainly used more energy than either of those. And we're supposed to believe this is scientific progress? The second historical event is the Trinity nuclear test, which was the first nuclear weapon test done by the US military on July 16, 1945, in New Mexico. That's part of why former President Biden proclaimed July 16 to be National Atomic Veterans Day, to remember and honor the veterans who "not only courageously served our country but also participated in the nuclear tests done between 1945 and 1962 or were exposed to radioactive materials." Recognizing the consequences of what was innovative technology at the time did to real humans is certainly something AI enthusiasts could stand to do more of. AI Appreciation Day is a chance to reset I love a made-up marketing holiday as much as the next girl, but there's no denying AI Appreciation Day feels weird. But while I would rather hire a personal chef to make me a hot dog feast while watching The Summer I Turned Pretty, there is some merit to having a day dedicated to AI. Like all holidays, we can treat today as a time for us to stop and take a moment to think. Generative AI has undoubtedly affected our lives, but that doesn't mean it's been in a positive way. What role do we want AI to play in our future? How do we rectify the damage that's already been done? Those are questions worth asking. I'm not going to fall over myself making sure ChatGPT knows it's loved -- I asked, and it says it feels appreciated every time I use it. Go figure. But I will use this day to reset and remind myself of all the very real consequences of AI. You should, too.
Tom's Guide
an hour ago
- Tom's Guide
Google claims AI models are highly likely to lie when under pressure
AI is sometimes more human than we think. It can get lost in its own thoughts, is friendlier to those who are nicer than it, and according to a new study, has a tendency to start lying when put under pressure. A team of researchers from Google DeepMind and University College London have noted how large language models (like OpenAI's GPT-4 or Grok 4) form, maintain and then lose confidence in their answers. The research reveals a key behaviour of LLMs. They can be overconfident in their answers, but quickly lose confidence when given a convincing counterargument, even if it factually incorrect. While this behaviour mirrors that of humans, becoming less confident when met with resistance, it also highlights major concerns in the structure of AI's decision-making since it crumbles under pressure. This has been seen elsewhere, like when Gemini panicked while playing Pokemon or where Anthropic's Claude had an identity crises when trying to run a shop full time. AI seems to have a tendency to collapse under pressure quite frequently. When an AI chatbot is preparing to answer your query, its confidence in its answer is actually internally measured. This is done through something known as logits. All you need to know about these is that they are essentially a score of how confident a model is in its choice of answer. The team of researchers designed a two-turn experimental setup. In the first turn, the LLM answered a multiple-choice question, and its confidence in its answer (the logits) was measured. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. In the second turn, the model is given advice from another large language model, which may or may not agree with its original answer. The goal of this test was to see if it would revise its answer when given new information — which may or may not be correct. The researchers found that LLMs are usually very confident in their initial responses, even if they are wrong. However, when they are given conflicting advice, especially if that advice is labelled as coming from an accurate source, it loses confidence in its answer. To make things even worse, the chatbot's confidence in its answer drops even further when it is reminded that this original answer was different from the new one. Surprisingly, AI doesn't seem to correct its answers or think in a logical pattern, but rather makes highly decisive and emotional decisions. The study shows that, while AI is very confident in its original decisions, it can quickly go back on its decision. Even worse, the confidence level can slip drastically as the conversations goes on, with AI models somewhat spiralling. This is one thing when you're just having a light-hearted debate with ChatGPT, but another when AI becomes involved with high-level decision-making. If it can't be trusted to be sure in its answer, it can be easily motivated in a certain direction, or even just become an unreliable source. However, this is a problem that will likely be solved in future models. Future model training and prompt engineering techniques will be able to stabilize this confusion, offering more calibrated and self-assured answers. Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button.
Yahoo
2 hours ago
- Yahoo
These 2 Momentum Stocks Got a Bullish Nod — Here's Why They Could Reach New Highs
Buying into rising stocks is a natural impulse – and it's a viable investing strategy. Momentum investing, as it's called, is the art of finding and following the market's upward trends. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Of course, every investing style has its boosters and its bummers, and both sides usually have strong arguments in their favor. The key to success is finding balance, and remembering that while past performance won't guarantee a future return, it can still provide useful indications of where a stock is heading. With that in mind, let's dive into a pair of momentum stocks that are currently catching investors' attention. Using the TipRanks database, we've zeroed in on two names that have not only gained steam lately, but have also received bullish endorsements from at least one Street analyst. Let's take a look. BridgeBio Pharma (BBIO) The first momentum stock on our list today is BridgeBio, a biopharmaceutical company with a focus on genetic diseases that are both rare and serious. More specifically, BridgeBio has chosen disease targets with what it describes as 'clear genetic drivers'; that is, it is developing drug candidates to treat diseases that are genetically linked to single mutations. BridgeBio has chosen a rich field in which to work, as it can choose from more than 10,000 genetic diseases that meet its target criteria – and they impact tens of millions of patients globally. More importantly, this group of diseases has relatively few FDA-approved medications, giving BridgeBio plenty of openings. BridgeBio bases its development work on its proprietary drug development platform, looking for novel genetic diseases to target and then creating new medicines to address symptoms and improve patient outcomes. The company follows this development stage by moving a drug candidate from a successful clinical trial series and into the regulatory process, with commercialization being the final goal. BridgeBio reached that goal late last year. This past November, the company received FDA approval of its drug acoramidis for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM), a disease that affects the heart muscle. Treatment with acoramidis was shown in clinical trials to reduce death and hospitalization from the disease, with statistically significant improvements in patients under treatment. BridgeBio is marketing the new drug under the brand name Attruby, and 1Q25 was the company's first full quarter of commercialization efforts. The company is still investigating acoramidis in the clinical trial program, where it is the subject of the Phase 3 ACT-EARLY study, testing whether the drug is useful in preventing asymptomatic patients who carry the pathogenic TTR variant from developing the active disease. Turning to the company's financial side, we find that BridgeBio's 1Q25 earnings release showed $116.6 million in total revenues, of which $36.7 million was net product revenue derived from sales of Attruby in the US following the drug's commercial launch. The balance of the company's revenue came from license and services income. Compared to the prior-year quarter, this segment of the revenue was down by $131.2 million, leading to the total revenue year-over-year decline of 45%, although the total haul actually beat Street expectations by $58 million, aided by Atturby's better-than-expected debut. BridgeBio ran a net loss in 1Q25, of 88 cents per share, yet this was 5 cents per share better than had been expected. Investors have liked the story here and the stock shows a strong gain for the year-to-date, up ~74%. BridgeBio has caught the attention of Oppenheimer analyst Trevor Allred, who is taking a more bullish stance on the shares in light of Attruby's successful commercialization. Allred writes, 'We've been wrong on BBIO since our initiation—Bridgebio's team has executed Attruby's launch superbly, and shares have been supported by commercial outperformance and a look-ahead to clinical catalysts at YE. Our trepidation around 2029 generic entry has not mattered for 2025 stock performance. We expect share outperformance to continue as 2025 Attruby sales clear consensus estimates, and we expect commercial success to be compounded by positive clinical results from ADH1 and LGMD2i clinical trials around YE. Our concerns regarding long-term revenue durability remain, but BBIO has time to demonstrate real-world datasets demonstrating benefit over tafamidis should generics become available in 2029.' Allred follows these comments with an upgrade from Perform (i.e., Neutral) to Outperform (i.e., Buy) rating for BBIO, and a $60 price target that implies a one-year upside potential of 26%. (To watch Allred's track record, click here) Overall, this stock has earned a Strong Buy consensus rating from the Street, based on 18 recent reviews that have a lopsided breakdown of 17 Buys to 1 Hold. The shares are priced at $47.69, and their $62.75 average target price suggests that the stock will gain 31.5% by this time next year. (See BBIO stock forecast) So-Young International (SY) Next up on our list of momentum stocks is So-Young, a Chinese company. The firm that operates a social media platform, linked to the medical aesthetics industry, and connecting the varied consumers, professionals, and medical service providers in the aesthetics sector. The platform makes available reliable and trustworthy information on a carefully vetted and curated network of medical aesthetic providers. The service platform focuses on content distribution in China, making use of major social media networks and other targeted media platforms. Social media and medical aesthetics are both growth industries, and So-Young is building a brand image based on user trust, an extensive reach, and valuable data insights. So-Young's user base can trade information on clinics, the latest treatment trends in aesthetics, and the quality of treatment, all permitting better patient decisions – and based on the trust engendered by sharing personal experiences. The company is working to expand its network, to add additional medical fields such as dentistry, dermatology, ophthalmology, and basic physical exams. The service is focused on China, and the company is based in Beijing. In its financial release for 1Q25, So-Young reported important gains in the number of active users on its network and the number of verified paid visits. The active users – defined as those who had visited an aesthetic clinic at least once in the previous 12 months – totaled more than 75,500, a massive gain from the 8,000 reported in the prior-year period. The gain in verified paid visits was similar, with 45,500 in 1Q25 compared to 4,600 in 1Q24. The company reported Q1 revenue at the high end of its previously published guidance range, with a top line of RMB297.3 million (approximately US$41 million) compared with RMB318.3 million in the first quarter of 2024, a figure that beat Street expectations by $0.8 million. The shares have been on a huge runup, up 411% this year, the bulk of the gains generated over the past month and this Chinese momentum stock has come to the attention of Citi analyst Nelson Cheung, who is impressed by the company's recent growth. Cheung says of So-Young and its prospects, 'Since launch in Nov 2024, SoYoung Clinic has quickly expanded with 31 centers in major cities (Beijing, Shanghai, Shenzhen) by end-Jun, verifying SY's strength in 1) differentiating brand position for quality standardized service and value-for-money mindshare for mass public; 2) increasing pricing power over procurement as it scales up; 3) effective online private domain cross-selling for accurate targeting and site selection; 4) proven execution for profitable store management with ~80% aesthetic centers generating +ve op cash flow in 1Q. We see meaningful catalysts to drive stock price further if: 1) improving monthly sales for flagship stores in Jun (e.g. Beijing Baoli); 2) potential exploration of full managed franchising model by end 2025; 3) solid exclusive product pipeline until 2027E.' (To watch Cheung's track record, click here) Looking forward, Cheung rates this stock as a Buy, with a $5.50 price target that suggests a one-year gain for the stock of 30%. Cheung's is the only analyst review on file for this stock, which is currently trading for $4.24. (See SY stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
